• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email
    SC 13G/A 1 c110569_sc13ga.htm

     

    SECURITIES AND EXCHANGE
    COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Oragenics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    684023500

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
    CUSIP No: 684023500
      (1) Names of Reporting Persons
    Iroquois Capital Management L.L.C.
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0 shares of Common Stock
     
    (6) Shared Voting Power
    0 shares of Common Stock

     
    (7) Sole Dispositive Power
    0 shares of Common Stock
     
    (8) Shared Dispositive Power
    0 shares of Common Stock

      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    0

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    0.0%
      (12) Type of Reporting Person (See Instructions)
    OO
     
    CUSIP No: 684023500
      (1) Names of Reporting Persons
    Richard Abbe
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power

    0 shares of Common Stock

     
    (6) Shared Voting Power
    0 shares of Common Stock
     
    (7)

    Sole Dispositive Power
    0 shares of Common Stock

     
    (8) Shared Dispositive Power
    0 shares of Common Stock
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares of Common Stock
      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    0.0%
      (12) Type of Reporting Person (See Instructions)
    IN; HC
     
    CUSIP No: 684023500
      (1) Names of Reporting Persons
    Kimberly Page
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0 shares of Common Stock
     
    (6) Shared Voting Power
    0 shares of Common Stock
     
    (7) Sole Dispositive Power
    0 shares of Common Stock
     
    (8) Shared Dispositive Power
    0 shares of Common Stock

     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares of Common Stock
      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    0.0%
      (12) Type of Reporting Person (See Instructions)
    IN
     

    CUSIP No: 684023500

     

    This Amendment No. 1 (this “Amendment”) amends the statement on Schedule 13G filed on September 11, 2024 (the “Original Schedule 13G”) with respect to the Common Stock, $0.001 par value (the “Common Stock”) of Oragenics, Inc. (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment amends and restates Item 4 and Item 5 in their entirety as set forth below.

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 11,255,728 shares of Common Stock issued and outstanding as of October 21, 2024 as represented in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 31, 2024.

     

    Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of ICIG. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   x

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024      
           
      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
           
      By:   /s/ Richard Abbe  
        Richard Abbe, President  
           
      /s/ Richard Abbe  
      Richard Abbe  
         
      /s/ Kimberly Page  
      Kimberly Page  
         
    523150391v.1    
     
    Get the next $OGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    SEC Filings

    View All

    Oragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    8/11/25 8:30:46 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Oragenics Inc.

    10-Q - ORAGENICS INC (0001174940) (Filer)

    8/8/25 4:16:17 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    7/2/25 4:30:18 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oragenics Q2 2025 Shareholder Update

    Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategic and financial milestones achieved during the second quarter of 2025 and shortly thereafter. These successes underscore the company's momentum as it strives to transform neurotrauma care and advance its lead candidate, ONP-002, toward becoming the first FDA-approved pharmacological treatment for concussion. "We're not just developing anot

    8/11/25 8:45:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

    SARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company's lead drug candidate for concussion. Southern Star Research is a globally recognized, full-service CRO with a proven track record in delivering early-phase trials across Australia and Asia-Pacific. Their deep operational expertise, regulatory knowledge, and hands-on site management capabilities will support the execution of Oragenics' randomized

    7/31/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

    SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion. This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. T

    7/16/25 8:39:31 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Goldman Sachs initiated coverage on Oragenics with a new price target

    Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

    6/3/21 6:23:39 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Odyssey Health, Inc. sold $30,407 worth of Common Stock - OGEN (7,044 units at $4.32), closing all direct ownership in the company (SEC Form 4)

    4 - ORAGENICS INC (0001174940) (Issuer)

    6/18/25 5:10:06 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Odyssey Health, Inc. sold $43,600 worth of Common Stock - OGEN (10,000 units at $4.36), decreasing direct ownership by 59% to 7,044 units (SEC Form 4)

    4 - ORAGENICS INC (0001174940) (Issuer)

    6/16/25 6:01:26 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Odyssey Health, Inc. claimed ownership of 249,623 units of Series F Preferred Stock and claimed ownership of 17,044 shares (SEC Form 3)

    3 - ORAGENICS INC (0001174940) (Issuer)

    6/16/25 5:54:50 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

    SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

    2/24/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

    SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

    5/22/24 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Oragenics Inc.

    SC 13G - ORAGENICS INC (0001174940) (Subject)

    9/11/24 7:45:36 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Financials

    Live finance-specific insights

    View All

    Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

    TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

    2/12/21 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care